Everything below concerns research peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-09. Numbers and descriptions here follow the published literature rather than marketing material.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
=== ICD-11 === The eleventh revision of the International Classification of Diseases, commonly referred to as ICD-11, conceptualizes diagnosis somewhat differently. ICD-11 first distinguishes between problems with psychoactive substance use ("Disorders due to substance use") and behavioral addictions ("Disorders due to addictive behaviours"). With regard to psychoactive substances, ICD-11 explains that the included substances initially produce "pleasant or appealing psychoactive effects that are rewarding and reinforcing with repeated use, [but] with continued use, many of the included substances have the capacity to produce dependence. They have the potential to cause numerous forms of harm, both to mental and physical health." Instead of the DSM-5 approach of one diagnosis ("Substance Use Disorder") covering all types of problematic substance use, ICD-11 offers three diagnostic possibilities: 1) Episode of Harmful Psychoactive Substance Use, 2) Harmful Pattern of Psychoactive Substance Use, and 3) Substance Dependence.
=== Impact upon beta cells === Because it selectively kills the insulin-producing beta-cells found in the pancreas, alloxan is used to induce diabetes in laboratory animals. This occurs most likely because of selective uptake of the compound due to its structural similarity to glucose as well as the beta-cell's highly efficient uptake mechanism (GLUT2). In addition, alloxan has a high affinity to SH-containing cellular compounds and, as a result, reduces glutathione content. Furthermore, alloxan inhibits glucokinase, a SH-containing protein essential for insulin secretion induced by glucose. Most studies have shown that alloxan is not toxic to the human beta-cell, even in very high doses, probably because of differing glucose uptake mechanisms in humans and rodents. Alloxan is, however, toxic to the liver and the kidneys in high doses, as these are tissues where the GLUT2 transporter is expressed in humans.
== Further reading == Hsu, Jeremy (May 23, 2025). "Trump's Golden Dome defence project could spur a space arms race". New Scientist. Retrieved May 27, 2025. Hennigan, W.J. (May 20, 2025). "The Reality of Trump's Golden Dome". The New York Times. Retrieved May 27, 2025. Mitchell, Ellen (May 4, 2025). "5 things to know as Trump rolls out Golden Dome missile defense shield". The Hill. Retrieved May 6, 2025. Maidenberg, Micah; Fitzgerald, Drew (May 4, 2025). "Everyone Wants a Piece of Trump's 'Golden Dome' Defense Plan". The Wall Street Journal. Retrieved May 6, 2025. Scoles, Sarah, "Dome's Long Shot: Golden Dome calls for missile interceptors in orbit to defend the U.S. Companies are already lining up to build a system that doesn't yet exist", Scientific American, vol. 335, no. 2 (September 2026), pp. 80–81. "In [the view of Todd] Harrison [a senior fellow at the American Enterprise Institute], it'll be a good long while before anyone knows how many thousands of interceptors will be in orbit or how they'll mesh with the rest of the dome. By the time the architecture is even set, he says, Golden Dome will probably have changed forms, been canceled and been resurrected with a different name." (p. 81.)
=== Other uses in arts, entertainment, and media === Mass (2004 film), Indian Telugu-language film Mass (2021 film), American drama film Mass (novel), a 1973 novel by Filipino author F. Sionil José The Masses, a socialist magazine published in the US from 1911 to 1917
=== 20th century === The oldest United States–based think tank, the Carnegie Endowment for International Peace, was founded in Washington, D.C., in 1910 by philanthropist Andrew Carnegie. Carnegie charged trustees to use the fund to "hasten the abolition of international war, the foulest blot upon our civilization." The Brookings Institution was founded shortly thereafter in 1916 by Robert S. Brookings and was conceived as a bipartisan "research center modeled on academic institutions and focused on addressing the questions of the federal government." After 1945, the number of policy institutes increased, with many small new ones forming to address Cold War geopolitics and post-war reconstruction, aiming to express various issues and policy agendas. Until the 1940s, most think tanks were known only by the name of the institution. During the Second World War, think tanks were often referred to as "brain boxes". Before the 1950s, the phrase "think tank" did not refer to organizations. From its first appearances in the 1890s up to the 1950s, the phrase was most commonly used in American English to colloquially refer to the braincase or especially in a pejorative context to the human brain itself when commenting on an individual's failings (in the sense that something was wrong with that person's "think tank"). Around 1958, the first organization to be regularly described in published writings as "the Think Tank" (note the title case and the use of the definite article) was the Center for Advanced Study in the Behavioral Sciences.
Sources: en.wikipedia.org
By 1974, another challenge to the state's authority and legitimacy came from the 19th of April Movement (M-19), leading to a new phase in the conflict. The M-19 was a mostly urban guerrilla group, founded in response to alleged electoral fraud during the final National Front election of Misael Pastrana Borrero (1970–1974) against former President Gustavo Rojas Pinilla.
== Controversies == During the Second World War, Roche was reported to have collaborated with the Nazi regime in Germany and used prisoners-of-war or foreign forced labour in its German and Polish-based factories. In 2008 the Association of the British Pharmaceutical Industry (ABPI) suspended Roche for six months for breaching their code of conduct. In 2013, Roche had to pay back SFr 3.2 billion to the Swiss tax authorities due to transfer mispricing.
Alkaloids are bitter-tasting chemicals, widespread in nature, and often toxic. There are several classes with different modes of action as drugs, both recreational and pharmaceutical. Medicines of different classes include atropine, scopolamine, and hyoscyamine (all from nightshade), the traditional medicine berberine (from plants such as Berberis and Mahonia), caffeine (Coffea), cocaine (Coca), ephedrine (Ephedra), morphine (opium poppy), nicotine (tobacco), reserpine (Rauvolfia serpentina), quinidine and quinine (Cinchona), vincamine (Vinca minor), and vincristine (Catharanthus roseus).
=== Protocol example === A ZooMS protocol (Fig. 1) typically consists of an extraction, denaturation, digestion and filtration step, followed by mass spectrometric analysis. Various destructive and non-destructive extraction protocols have already been discussed in some detail above. The key is to extract the protein preserved in the sample and then bring it into solution, usually an ammonium bicarbonate buffer. Denaturation is done to unfold the proteins and make them more accessible for the enzymatic digestion. It is done by heating the solubilised sample at around 65 °C. Then an enzyme, trypsin, is added to the solution. Trypsin cleaves the protein after every arginine or lysine amino acid in its sequence, resulting in peptide fragments of predictable masses. After digestion the sample is filtered with C18 filters to get rid of non-proteinaceous material and the sample is now ready for mass spectrometric analysis, which for ZooMS generally means MALDI-TOF MS.
Sexual dysfunction, including loss of libido, erectile dysfunction, lack of vaginal lubrication, and anorgasmia, are some of the most commonly encountered adverse effects of treatment with fluoxetine and other SSRIs. While early clinical trials suggested a relatively low rate of sexual dysfunction, more recent studies in which the investigator actively inquires about sexual problems suggest that the incidence is >70%. In 2019, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended that packaging leaflets of selected SSRIs and SNRIs should be amended to include information regarding a possible risk of persistent sexual dysfunction. Following on the European assessment, a safety review by Health Canada "could neither confirm nor rule out a causal link ... which was long lasting in rare cases", but recommended that "healthcare professionals inform patients about the potential risk of long-lasting sexual dysfunction despite discontinuation of treatment".
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.